name,skill_name,Individuals
Judith Palou,Drug delivery,4
Rok Dreu,Drug delivery,4
Martin de Kort,Drug delivery,4
Drug Discovery Group,Drug delivery,5
Claudia Fuchs,Drug delivery,4
Alicia Soler Cantón,Drug delivery,4
Communication and Project Management Group,Legal expertise,3
Martin de Kort,Legal expertise,2
Carmine Talarico,Legal expertise,2
Andrea Beccari,Legal expertise,2
Martin de Kort,Drug Formulation,3
Alicia Soler Cantón,Drug Formulation,3
Drug Discovery Group,Drug Formulation,4
Judith Palou,Drug Formulation,3
Rok Dreu,Drug Formulation,3
Drug Development Group,Health technology assessment,7
Maddalena Fratelli,Health technology assessment,6
Dalma Hosszú,Health technology assessment,6
Heleen van der Meer,Health technology assessment,6
Zoltán Kaló,Health technology assessment,6
Zsuzsanna Petykó,Health technology assessment,6
Marcell Csanádi,Health technology assessment,6
András Inotai,Health technology assessment,6
Drug Discovery Group,In-vivo toxicity testing,2
Martin de Kort,In-vivo toxicity testing,1
Philip Gribbon,In-vivo toxicity testing,1
András Inotai,Market access,7
Zsuzsanna Petykó,Market access,7
Anne Heß,Market access,7
Marcell Csanádi,Market access,7
Judith Palou,Market access,7
Dalma Hosszú,Market access,7
Drug Development Group,Market access,8
Heleen van der Meer,Market access,7
Zoltán Kaló,Market access,7
Johanna Huchting,Pro-drugs,3
Judith Palou,Pro-drugs,3
Drug Discovery Group,Pro-drugs,4
Davide Graziani,Pro-drugs,3
Andrea Zaliani,Pro-drugs,3
Tero Aittokallio,High-throughput screening (HTS),19
Philip Gribbon,High-throughput screening (HTS),19
Annika Jenmalm Jensen,High-throughput screening (HTS),19
Annika Jensen,High-throughput screening (HTS),19
Markus Vähä-Koskela,High-throughput screening (HTS),19
Marc Jacobs,High-throughput screening (HTS),19
Aimo Kannt,High-throughput screening (HTS),19
Alessandra Leone,High-throughput screening (HTS),19
Francesca Bruzzese,High-throughput screening (HTS),19
Andrea Zaliani,High-throughput screening (HTS),19
Johanna Huchting,High-throughput screening (HTS),19
Anna-Lena Gustavsson,High-throughput screening (HTS),19
Jani Saarela,High-throughput screening (HTS),19
Brinton Seashore-Ludlow,High-throughput screening (HTS),19
Drug Discovery Group,High-throughput screening (HTS),20
Jeanette Reinshagen,High-throughput screening (HTS),19
Marianna Tampere,High-throughput screening (HTS),19
Swapnil Potdar,High-throughput screening (HTS),19
Päivi Östling,High-throughput screening (HTS),19
Davide Graziani,High-throughput screening (HTS),19
Jordi Carreras-Puigvert,High-throughput screening (HTS),19
Flavio Ballante,Hit-to-lead (HTL) | lead generation,11
Davide Graziani,Hit-to-lead (HTL) | lead generation,11
Aimo Kannt,Hit-to-lead (HTL) | lead generation,11
Philip Gribbon,Hit-to-lead (HTL) | lead generation,11
Anna-Lena Gustavsson,Hit-to-lead (HTL) | lead generation,11
Martin de Kort,Hit-to-lead (HTL) | lead generation,11
Andrea Zaliani,Hit-to-lead (HTL) | lead generation,11
Andrea Beccari,Hit-to-lead (HTL) | lead generation,11
Annika Jensen,Hit-to-lead (HTL) | lead generation,11
Carmine Talarico,Hit-to-lead (HTL) | lead generation,11
Drug Discovery Group,Hit-to-lead (HTL) | lead generation,12
Jordi Quintana,Hit-to-lead (HTL) | lead generation,11
Annika Jenmalm Jensen,Hit-to-lead (HTL) | lead generation,11
Aimo Kannt,Biological discovery,11
Sofia Sintoris,Biological discovery,11
Markus Vähä-Koskela,Biological discovery,11
Martin Hofmann-Apitius,Biological discovery,11
Yojana Gadiya,Biological discovery,11
Francesca Bruzzese,Biological discovery,11
Claudia Fuchs,Biological discovery,11
Drug Discovery Group,Biological discovery,12
Maddalena Fratelli,Biological discovery,11
Brinton Seashore-Ludlow,Biological discovery,11
Anna-Lena Gustavsson,Biological discovery,11
Katja Herzog,Biological discovery,11
Alicia Soler Cantón,Biological discovery,11
Drug Development Group,Data management,7
Jordi Quintana,Data management,6
Philip Gribbon,Data management,6
Martin Hofmann-Apitius,Data management,6
Marc Jacobs,Data management,6
Swapnil Potdar,Data management,6
Andrea Zaliani,Data management,6
Tero Aittokallio,Data management,6
Drug Discovery Group,In-vitro toxicity testing - Ames,1
Carmine Talarico,In-vivo modelling,2
Sarai Rodríguez Navarro,In-vivo modelling,2
Drug Discovery Group,In-vivo modelling,3
Martin de Kort,In-vivo modelling,2
Martin de Kort,Target validation,10
Carmine Talarico,Target validation,10
Annika Jenmalm Jensen,Target validation,10
Aimo Kannt,Target validation,10
Drug Discovery Group,Target validation,11
Andrea Zaliani,Target validation,10
Anna-Lena Gustavsson,Target validation,10
Claudia Fuchs,Target validation,10
Annika Jensen,Target validation,10
Philip Gribbon,Target validation,10
Jordi Carreras-Puigvert,Target validation,10
Alessandra Leone,Target validation,10
Judith Palou,Project communication and dissemination,23
Communication and Project Management Group,Project communication and dissemination,24
Saco de Visser,Project communication and dissemination,23
Katja Herzog,Project communication and dissemination,23
Pan Pantziarka,Project communication and dissemination,23
Marcell Csanádi,Project communication and dissemination,23
Jeanette Reinshagen,Project communication and dissemination,23
Marianna Tampere,Project communication and dissemination,23
Jordi Carreras-Puigvert,Project communication and dissemination,23
Tero Aittokallio,Project communication and dissemination,23
Carmine Talarico,Project communication and dissemination,23
Sarai Rodríguez Navarro,Project communication and dissemination,23
Berta Gumí Audenis,Project communication and dissemination,23
Gisela Pairó,Project communication and dissemination,23
Claudia Fuchs,Project communication and dissemination,23
Maddalena Fratelli,Project communication and dissemination,23
Anna-Lena Gustavsson,Project communication and dissemination,23
Ivette Corominas,Project communication and dissemination,23
Alicia Soler Cantón,Project communication and dissemination,23
Zsuzsanna Petykó,Project communication and dissemination,23
Martin Hofmann-Apitius,Project communication and dissemination,23
Sofia Sintoris,Project communication and dissemination,23
Federica Righi,Project communication and dissemination,23
Dalma Hosszú,Project communication and dissemination,23
Francesca Bruzzese,Project communication and dissemination,23
Judith Palou,Clinical study report (CSR) creation,1
Drug Development Group,Clinical study report (CSR) creation,2
Keiko Ueda,Clinical study report (CSR) creation,1
Drug Development Group,Marketing authorization application (MAA),4
Peggy Beinlich,Marketing authorization application (MAA),3
Alicia Soler Cantón,Marketing authorization application (MAA),3
Carmine Talarico,Marketing authorization application (MAA),3
Andrea Beccari,Marketing authorization application (MAA),3
Ziaurrehman Tanoli,Target identification,17
Annika Jenmalm Jensen,Target identification,17
Martin Hofmann-Apitius,Target identification,17
Andrea Zaliani,Target identification,17
Judith Palou,Target identification,17
Annika Jensen,Target identification,17
Flavio Ballante,Target identification,17
Yojana Gadiya,Target identification,17
Jordi Carreras-Puigvert,Target identification,17
Pan Pantziarka,Target identification,17
Tero Aittokallio,Target identification,17
Drug Discovery Group,Target identification,18
Aimo Kannt,Target identification,17
Philip Gribbon,Target identification,17
Claudia Fuchs,Target identification,17
Anna-Lena Gustavsson,Target identification,17
Brinton Seashore-Ludlow,Target identification,17
Carmine Talarico,Target identification,17
Jordi Quintana,Target identification,17
Drug Development Group,Quality assurance (clinical trials),1
Annika Jensen,Hit confirmation | hit validation,14
Andrea Beccari,Hit confirmation | hit validation,14
Annika Jenmalm Jensen,Hit confirmation | hit validation,14
Davide Graziani,Hit confirmation | hit validation,14
Brinton Seashore-Ludlow,Hit confirmation | hit validation,14
Jordi Quintana,Hit confirmation | hit validation,14
Andrea Zaliani,Hit confirmation | hit validation,14
Carmine Talarico,Hit confirmation | hit validation,14
Philip Gribbon,Hit confirmation | hit validation,14
Aimo Kannt,Hit confirmation | hit validation,14
Jordi Carreras-Puigvert,Hit confirmation | hit validation,14
Jeanette Reinshagen,Hit confirmation | hit validation,14
Anna-Lena Gustavsson,Hit confirmation | hit validation,14
Johanna Huchting,Hit confirmation | hit validation,14
Drug Discovery Group,Hit confirmation | hit validation,15
Marianna Tampere,Hit confirmation | hit validation,14
Francesca Bruzzese,Drug combinations,10
Sarai Rodríguez Navarro,Drug combinations,10
Tero Aittokallio,Drug combinations,10
Andrea Zaliani,Drug combinations,10
Brinton Seashore-Ludlow,Drug combinations,10
Judith Palou,Drug combinations,10
Drug Discovery Group,Drug combinations,11
Jani Saarela,Drug combinations,10
Martin de Kort,Drug combinations,10
Alessandra Leone,Drug combinations,10
Maddalena Fratelli,Drug combinations,10
Jordi Carreras-Puigvert,Drug combinations,10
Brinton Seashore-Ludlow,Pre-clinical pharmacology,13
Carmine Talarico,Pre-clinical pharmacology,13
Claudia Fuchs,Pre-clinical pharmacology,13
Sarai Rodríguez Navarro,Pre-clinical pharmacology,13
Marianna Tampere,Pre-clinical pharmacology,13
Francesca Bruzzese,Pre-clinical pharmacology,13
Maddalena Fratelli,Pre-clinical pharmacology,13
Jeanette Reinshagen,Pre-clinical pharmacology,13
Judith Palou,Pre-clinical pharmacology,13
Tero Aittokallio,Pre-clinical pharmacology,13
Martin de Kort,Pre-clinical pharmacology,13
Drug Development Group,Pre-clinical pharmacology,14
Andrea Zaliani,Pre-clinical pharmacology,13
Andrea Beccari,Pre-clinical pharmacology,13
Aimo Kannt,Pre-clinical pharmacology,13
Communication and Project Management Group,Ethics and ELSI,1
Zoltán Kaló,Phase 3 trials,7
Judith Palou,Phase 3 trials,7
Andrea Beccari,Phase 3 trials,7
Keiko Ueda,Phase 3 trials,7
Drug Development Group,Phase 3 trials,8
Saco de Visser,Phase 3 trials,7
Alessandra Leone,Phase 3 trials,7
Carmine Talarico,Phase 3 trials,7
Heleen van der Meer,Phase 3 trials,7
Drug Development Group,Phase 1 trials,8
Claudia Fuchs,Phase 1 trials,7
Andrea Beccari,Phase 1 trials,7
Saco de Visser,Phase 1 trials,7
Carmine Talarico,Phase 1 trials,7
Martin de Kort,Phase 1 trials,7
Alessandra Leone,Phase 1 trials,7
Keiko Ueda,Phase 1 trials,7
Judith Palou,Phase 1 trials,7
Drug Development Group,Investigational new drug (IND) submission,6
Carmine Talarico,Investigational new drug (IND) submission,5
Alicia Soler Cantón,Investigational new drug (IND) submission,5
Keiko Ueda,Investigational new drug (IND) submission,5
Martin de Kort,Investigational new drug (IND) submission,5
Rok Dreu,Investigational new drug (IND) submission,5
Andrea Beccari,Investigational new drug (IND) submission,5
Sarai Rodríguez Navarro,Project management,33
Anna-Lena Gustavsson,Project management,33
Alicia Soler Cantón,Project management,33
Alessandra Leone,Project management,33
Communication and Project Management Group,Project management,34
Claudia Fuchs,Project management,33
Annika Jenmalm Jensen,Project management,33
Jordi Carreras-Puigvert,Project management,33
Aimo Kannt,Project management,33
Keiko Ueda,Project management,33
Andrea Beccari,Project management,33
Annika Jensen,Project management,33
Davide Graziani,Project management,33
András Inotai,Project management,33
Dalma Hosszú,Project management,33
Markus Vähä-Koskela,Project management,33
Martina Spadetto,Project management,33
Federica Righi,Project management,33
Carmine Talarico,Project management,33
Andrea Zaliani,Project management,33
Jordi Quintana,Project management,33
Brinton Seashore-Ludlow,Project management,33
Päivi Östling,Project management,33
Martin Hofmann-Apitius,Project management,33
Katja Herzog,Project management,33
Jani Saarela,Project management,33
Rok Dreu,Project management,33
Berta Gumí Audenis,Project management,33
Marc Jacobs,Project management,33
Zsuzsanna Petykó,Project management,33
Peggy Beinlich,Project management,33
Philip Gribbon,Project management,33
Marianna Tampere,Project management,33
Saco de Visser,Project management,33
Judith Palou,Project management,33
Marcell Csanádi,Health Economics,4
Drug Development Group,Health Economics,5
Zoltán Kaló,Health Economics,4
Dalma Hosszú,Health Economics,4
Zsuzsanna Petykó,Health Economics,4
András Inotai,Health Economics,4
Martin de Kort,Active pharmaceutical ingredient (API) manufacturing,3
Andrea Beccari,Active pharmaceutical ingredient (API) manufacturing,3
Drug Development Group,Active pharmaceutical ingredient (API) manufacturing,4
Andrea Zaliani,Active pharmaceutical ingredient (API) manufacturing,3
Alicia Soler Cantón,Active pharmaceutical ingredient (API) manufacturing,3
Andrea Beccari,Medicinal chemistry,12
Judith Palou,Medicinal chemistry,12
Johanna Huchting,Medicinal chemistry,12
Davide Graziani,Medicinal chemistry,12
Flavio Ballante,Medicinal chemistry,12
Drug Discovery Group,Medicinal chemistry,13
Yojana Gadiya,Medicinal chemistry,12
Ziaurrehman Tanoli,Medicinal chemistry,12
Andrea Zaliani,Medicinal chemistry,12
Jordi Quintana,Medicinal chemistry,12
Annika Jensen,Medicinal chemistry,12
Martin de Kort,Medicinal chemistry,12
Annika Jenmalm Jensen,Medicinal chemistry,12
Anna-Lena Gustavsson,Medicinal chemistry,12
Simon Žakelj,Absorption distribution metabolism elimination (ADME),6
Maddalena Fratelli,Absorption distribution metabolism elimination (ADME),6
Aimo Kannt,Absorption distribution metabolism elimination (ADME),6
Davide Graziani,Absorption distribution metabolism elimination (ADME),6
Andrea Zaliani,Absorption distribution metabolism elimination (ADME),6
Martin de Kort,Absorption distribution metabolism elimination (ADME),6
Drug Discovery Group,Absorption distribution metabolism elimination (ADME),7
Annika Jenmalm Jensen,Absorption distribution metabolism elimination (ADME),6
Drug Development Group,Analytical Techniques,4
Judith Palou,Analytical Techniques,3
Tero Aittokallio,Analytical Techniques,3
Maddalena Fratelli,Analytical Techniques,3
Alicia Soler Cantón,Analytical Techniques,3
Drug Development Group,Phase 4 trials and Pharmacovigilance,6
Saco de Visser,Phase 4 trials and Pharmacovigilance,5
Carmine Talarico,Phase 4 trials and Pharmacovigilance,5
Zoltán Kaló,Phase 4 trials and Pharmacovigilance,5
Andrea Beccari,Phase 4 trials and Pharmacovigilance,5
Judith Palou,Phase 4 trials and Pharmacovigilance,5
Heleen van der Meer,Phase 4 trials and Pharmacovigilance,5
Sarai Rodríguez Navarro,Patient related documentation creation,3
Alicia Soler Cantón,Patient related documentation creation,3
Pan Pantziarka,Patient related documentation creation,3
Drug Development Group,Patient related documentation creation,4
Claudia Fuchs,Patient related documentation creation,3
Andrea Zaliani,Mechanism of action (MoA),20
Ziaurrehman Tanoli,Mechanism of action (MoA),20
Marianna Tampere,Mechanism of action (MoA),20
Aimo Kannt,Mechanism of action (MoA),20
Marc Jacobs,Mechanism of action (MoA),20
Yojana Gadiya,Mechanism of action (MoA),20
Maddalena Fratelli,Mechanism of action (MoA),20
Jordi Quintana,Mechanism of action (MoA),20
Drug Discovery Group,Mechanism of action (MoA),21
Philip Gribbon,Mechanism of action (MoA),20
Andrea Beccari,Mechanism of action (MoA),20
Flavio Ballante,Mechanism of action (MoA),20
Anna-Lena Gustavsson,Mechanism of action (MoA),20
Alessandra Leone,Mechanism of action (MoA),20
Annika Jensen,Mechanism of action (MoA),20
Judith Palou,Mechanism of action (MoA),20
Claudia Fuchs,Mechanism of action (MoA),20
Jordi Carreras-Puigvert,Mechanism of action (MoA),20
Brinton Seashore-Ludlow,Mechanism of action (MoA),20
Martin de Kort,Mechanism of action (MoA),20
Francesca Bruzzese,Mechanism of action (MoA),20
Annika Jenmalm Jensen,Mechanism of action (MoA),20
Drug Discovery Group,Natural products,3
Andrea Zaliani,Natural products,2
Philip Gribbon,Natural products,2
Andrea Beccari,Natural products,2
Drug Development Group,Phase 2 trials,7
Andrea Beccari,Phase 2 trials,6
Alessandra Leone,Phase 2 trials,6
Martin de Kort,Phase 2 trials,6
Carmine Talarico,Phase 2 trials,6
Saco de Visser,Phase 2 trials,6
Keiko Ueda,Phase 2 trials,6
Judith Palou,Phase 2 trials,6
Drug Discovery Group,Pharmacokinetics (PK),9
Ziaurrehman Tanoli,Pharmacokinetics (PK),8
Igor Locatelli,Pharmacokinetics (PK),8
Martin de Kort,Pharmacokinetics (PK),8
Andrea Zaliani,Pharmacokinetics (PK),8
Aimo Kannt,Pharmacokinetics (PK),8
Davide Graziani,Pharmacokinetics (PK),8
Saco de Visser,Pharmacokinetics (PK),8
Maddalena Fratelli,Pharmacokinetics (PK),8
Judith Palou,Pharmacokinetics (PK),8
Zsuzsanna Petykó,Evidence synthesis,5
Heleen van der Meer,Evidence synthesis,5
András Inotai,Evidence synthesis,5
Drug Development Group,Evidence synthesis,6
Marcell Csanádi,Evidence synthesis,5
Dalma Hosszú,Evidence synthesis,5
Zoltán Kaló,Evidence synthesis,5
Drug Discovery Group,Pharmacodynamics (PD),7
Saco de Visser,Pharmacodynamics (PD),6
Andrea Zaliani,Pharmacodynamics (PD),6
Ziaurrehman Tanoli,Pharmacodynamics (PD),6
Judith Palou,Pharmacodynamics (PD),6
Aimo Kannt,Pharmacodynamics (PD),6
Maddalena Fratelli,Pharmacodynamics (PD),6
Martin de Kort,Pharmacodynamics (PD),6
Sarai Rodríguez Navarro,Medical writing,6
Zoltán Kaló,Medical writing,6
Zsuzsanna Petykó,Medical writing,6
Pan Pantziarka,Medical writing,6
Keiko Ueda,Medical writing,6
Drug Development Group,Medical writing,7
Heleen van der Meer,Medical writing,6
Claudia Fuchs,Medical writing,6
Sarai Rodríguez Navarro,In-vivo efficacy evaluation,3
Martin de Kort,In-vivo efficacy evaluation,3
Drug Discovery Group,In-vivo efficacy evaluation,4
Aimo Kannt,In-vivo efficacy evaluation,3
Francesca Bruzzese,In-vivo efficacy evaluation,3
Claudia Fuchs,Adaptive trial design,2
Martin de Kort,Adaptive trial design,2
Drug Development Group,Adaptive trial design,3
Päivi Östling,Adaptive trial design,2
Ziaurrehman Tanoli,Clinical statistics,4
Martin Hofmann-Apitius,Clinical statistics,4
Sofia Sintoris,Clinical statistics,4
Heleen van der Meer,Clinical statistics,4
Drug Development Group,Clinical statistics,5
Andrea Zaliani,Clinical statistics,4
Zoltán Kaló,Clinical study design,8
Heleen van der Meer,Clinical study design,8
Drug Development Group,Clinical study design,9
Saco de Visser,Clinical study design,8
Martin de Kort,Clinical study design,8
Alessandra Leone,Clinical study design,8
Aimo Kannt,Clinical study design,8
Keiko Ueda,Clinical study design,8
Zsuzsanna Petykó,Clinical study design,8
Francesca Bruzzese,Clinical study design,8
